Ballicules.com

Leuprolide

LUPRON

What it isGnRH receptor agonist causing downregulation; prostate cancer, endometriosis, fibroids and precocious puberty.

Why this oneIts broad depot range supports sustained suppression across oncology, gynecology, and precocious puberty.

What limits itAn initial testosterone flare requires antiandrogen cover in prostate cancer. Hot flushes and bone loss.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Advanced prostate cancer (palliative)Adults1 mg SC QD1 mg SC QD1 mg SC QD

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy May cause fetal harm based on animal data (malformations); no human data. Safety/efficacy not established in females.

Lactation No information; safety/efficacy not established in females.

NO BOXED WARNINGS

Principal riskTestosterone flare needing antiandrogen cover; bone loss

Cost, est. cash$10–$1,000/month

Generic entry1998

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades2 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk3 / 4

Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent

Defining liabilityThrombotic, metabolic, hepatic, skeletal or reproductive toxicity varies by hormonal target.

Mechanism of action: Leuprolide ballicule

Leuprolide ballicule: receptor binding, kinetics and half-life diagram

Open Leuprolide in the interactive console ↗

Memory aids: mascots and interaction avatars

Leuprolide LUPRON / ELIGARD mascot mnemonic cartoon
“Eligard Loops the nards (indirectly)”
QT prolongation
Leuprolide no kinetic interactions avatar
no kinetic interactions

Open Leuprolide in the interactive console ↗